These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 29556418)

  • 1. Identification of sarilumab pharmacodynamic and predictive markers in patients with inadequate response to TNF inhibition: a biomarker substudy of the phase 3 TARGET study.
    Gabay C; Msihid J; Zilberstein M; Paccard C; Lin Y; Graham NMH; Boyapati A
    RMD Open; 2018; 4(1):e000607. PubMed ID: 29556418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY.
    Boyapati A; Msihid J; Fiore S; van Adelsberg J; Graham NM; Hamilton JD
    Arthritis Res Ther; 2016 Oct; 18(1):225. PubMed ID: 27716324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes.
    Gabay C; Burmester GR; Strand V; Msihid J; Zilberstein M; Kimura T; van Hoogstraten H; Boklage SH; Sadeh J; Graham NMH; Boyapati A
    Arthritis Res Ther; 2020 Apr; 22(1):70. PubMed ID: 32264972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial.
    Huizinga TW; Fleischmann RM; Jasson M; Radin AR; van Adelsberg J; Fiore S; Huang X; Yancopoulos GD; Stahl N; Genovese MC
    Ann Rheum Dis; 2014 Sep; 73(9):1626-34. PubMed ID: 24297381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-6 receptor blockade or TNFα inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials.
    Genovese MC; Burmester GR; Hagino O; Thangavelu K; Iglesias-Rodriguez M; John GS; González-Gay MA; Mandrup-Poulsen T; Fleischmann R
    Arthritis Res Ther; 2020 Sep; 22(1):206. PubMed ID: 32907617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors.
    Strand V; Reaney M; Chen CI; Proudfoot CW; Guillonneau S; Bauer D; Mangan E; Graham NM; van Hoogstraten H; Lin Y; Pacheco-Tena C; Fleischmann R
    RMD Open; 2017; 3(1):e000416. PubMed ID: 28326189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.
    Fleischmann R; van Adelsberg J; Lin Y; Castelar-Pinheiro GD; Brzezicki J; Hrycaj P; Graham NM; van Hoogstraten H; Bauer D; Burmester GR
    Arthritis Rheumatol; 2017 Feb; 69(2):277-290. PubMed ID: 27860410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The predictive value of serum soluble ICAM-1 and CXCL13 in the therapeutic response to TNF inhibitor in rheumatoid arthritis patients who are refractory to csDMARDs.
    Zhao J; Ye X; Zhang Z
    Clin Rheumatol; 2020 Sep; 39(9):2573-2581. PubMed ID: 32206975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan.
    Tanaka Y; Wada K; Takahashi Y; Hagino O; van Hoogstraten H; Graham NMH; Kameda H
    Arthritis Res Ther; 2019 Mar; 21(1):79. PubMed ID: 30894208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis refractory to TNF inhibitors.
    Fleischmann R; Genovese MC; Maslova K; Leher H; Praestgaard A; Burmester GR
    Rheumatology (Oxford); 2021 Nov; 60(11):4991-5001. PubMed ID: 33871596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
    Strand V; Gossec L; Proudfoot CWJ; Chen CI; Reaney M; Guillonneau S; Kimura T; van Adelsberg J; Lin Y; Mangan EK; van Hoogstraten H; Burmester GR
    Arthritis Res Ther; 2018 Jun; 20(1):129. PubMed ID: 29921318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetic-Pharmacodynamic Relationships of Sarilumab Using Disease Activity Score 28-Joint C-Reactive Protein and Absolute Neutrophil Counts in Patients with Rheumatoid Arthritis.
    Ma L; Xu C; Paccaly A; Kanamaluru V
    Clin Pharmacokinet; 2020 Nov; 59(11):1451-1466. PubMed ID: 32451909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usability and Patient Preference Phase 3 Study of the Sarilumab Pen in Patients with Active Moderate-to-Severe Rheumatoid Arthritis.
    Kivitz A; Baret-Cormel L; van Hoogstraten H; Wang S; Parrino J; Xu C; Stanislav M
    Rheumatol Ther; 2018 Jun; 5(1):231-242. PubMed ID: 29209946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale.
    Gossec L; Strand V; Proudfoot C; Chen CI; Guillonneau S; Kimura T; van Hoogstraten H; Mangan E; Reaney M
    J Rheumatol; 2019 Oct; 46(10):1259-1267. PubMed ID: 30877216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment.
    Genovese MC; van der Heijde D; Lin Y; St John G; Wang S; van Hoogstraten H; Gómez-Reino JJ; Kivitz A; Maldonado-Cocco JA; Seriolo B; Stanislav M; Burmester GR
    RMD Open; 2019; 5(2):e000887. PubMed ID: 31452928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levels of CXCL13 and sICAM-1 correlate with disease activity score in patients with rheumatoid arthritis treated with tocilizumab.
    Tuckwell K; Gabay C; Sornasse T; Laubender RP; Wang J; Townsend MJ
    Adv Rheumatol; 2019 Dec; 59(1):54. PubMed ID: 31801637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs.
    Wells AF; Parrino J; Mangan EK; Paccaly A; Lin Y; Xu C; Fan C; Graham NMH; van Hoogstraten H; Torri A
    Rheumatol Ther; 2019 Sep; 6(3):339-352. PubMed ID: 31090044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Efficacy of Sarilumab Versus Upadacitinib Over 12 weeks: An Indirect Treatment Comparison.
    Huizinga T; Choy E; Praestgaard A; van Hoogstraten H; LaFontaine PR; Guyot P; Aletaha D; Müller-Ladner U; Tanaka Y; Curtis JR; Fleischmann R
    Rheumatol Ther; 2023 Jun; 10(3):539-550. PubMed ID: 36725768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: A Japan phase 3 trial (HARUKA).
    Kameda H; Wada K; Takahashi Y; Hagino O; van Hoogstraten H; Graham N; Tanaka Y
    Mod Rheumatol; 2020 Mar; 30(2):239-248. PubMed ID: 31268376
    [No Abstract]   [Full Text] [Related]  

  • 20. Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies.
    Ferrufino CP; Munakata J; Wei W; Proudfoot C; Kuznik A; Boklage SH; Chen CI
    Clinicoecon Outcomes Res; 2018; 10():805-819. PubMed ID: 30532571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.